Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 2/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.52 |
| ▸ | TTK | P33981 | 4/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | ULK1 | O75385 | 2/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403438 | 0.88 | INSR (0.67) | INSRALKLRRK2MAPK10MAPK9 | |
| SCHEMBL12886654 | 0.84 | MAPK10 (0.60) | INSRALKLRRK2MAPK10MAPK9 | |
| SCHEMBL12886378 | 0.83 | ULK1 (0.62) | INSRALKLRRK2MAPK10MAPK9 | |
| SCHEMBL3399758 | 0.82 | MAPK10 (0.54) | MAPK10IGF1R | |
| SCHEMBL12886401 | 0.81 | MAPK10 (0.55) | INSRALKLRRK2MAPK10MAPK9 | |
| SCHEMBL12886412 | 0.81 | MAPK10 (0.55) | INSRALKLRRK2MAPK10MAPK9 | |
| SCHEMBL12886655 | 0.80 | MAPK10 (0.56) | INSRALKLRRK2MAPK10MAPK9 | |
| SCHEMBL12886448 | 0.80 | MAPK10 (0.54) | INSRALKLRRK2MAPK10MAPK9 | |
| SCHEMBL12886415 | 0.79 | MAPK10 (0.53) | INSRALKLRRK2MAPK10MAPK9 | |
| SCHEMBL12886390 | 0.79 | MAPK10 (0.70) | INSRALKLRRK2MAPK10MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| EP-2249650-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GlaxoSmithKline LLC (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009105498-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105498-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | PTK2, JAK2, SRC | INSR 572/4885ALK 342/4885LRRK2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.